Hequan pharmaceutical, a subsidiary of Wuxi Apptec Co.Ltd(603259) , announced today that the company won all six core awards of the “CMO leading enterprise award” in 2022 and won the champion in four of them. With its industry-leading “capabilities”, “compatibility”, “expertise”, “quality”, “reliability” and “service”, Hequan pharmaceutical won the “CMO leading enterprise award” for the eighth time and won these six core awards for three consecutive years.
“CMO Leadership Awards” is jointly presented by American life science leader magazine and industry standard research (ISR), a market research organization. It aims to commend global high-quality cooperative R & D and production enterprises that show outstanding performance in “capabilities”, “expertise” and “quality”. In 2022, the evaluation team invited large, medium and small companies in Europe and the United States to strictly screen and comprehensively evaluate more than 86 contract production and service providers around 23 key indicators, covering Pharmaceutical and biopharmaceutical companies of different sizes around the world. With outstanding performance exceeding customer expectations, Hequan pharmaceutical not only stood out again in all six core awards, but also won the crown in the selection of four awards of “specialty”, “quality”, “reliability” and “service”, which demonstrates the high trust and recognition of global partners for Hequan pharmaceutical’s integrated CMC R & D, production and service capabilities.
Hequan pharmaceutical has been deeply engaged in the field of cdmo for more than 20 years. In 2021 alone, it provided services to more than 560 biomedical enterprises around the world. At present, the pipeline carries 1500 + new drug molecules, including 49 late stage clinical projects and 42 commercial projects. With the industry-leading integrated CMC enabling platform and the quality system in line with international standards, Hequan pharmaceutical has successfully supported its partners’ innovative drugs to be listed in 105 countries around the world in recent years.
Wuxi Apptec Co.Ltd(603259) co CEO Dr. Chen minzhang, CEO of Hequan pharmaceutical, said: “We are honored to once again win all six core awards of the ‘CMO leading enterprise award’, and thank our partners for their high trust and strong support to Hequan pharmaceutical. Hequan pharmaceutical has always been committed to providing global partners with high-quality, high standard and reliable one-stop CMC services. In the future, we will continue to improve the platform capability, continue to empower customers and accelerate the development process of innovative drugs For the benefit of patients. “
About Hequan pharmaceutical
Hequan pharmaceutical is a Wuxi Apptec Co.Ltd(603259) subsidiary with R & D and production bases in many places around the world. Hequan pharmaceutical serves the life science industry and has excellent R & D and production capacity and technical platform of chemical innovative drugs. As a leading enterprise in the field of global cooperative research, development and production of new drugs (cdmo), Hequan pharmaceutical is committed to providing global partners with efficient, flexible and high-quality one-stop solutions to support the R & D and production of small molecules, oligonucleotides, peptides and various complex chemically coupled drugs.
